Nobel laureate Carolyn Bertozzi on the launch of Firefly Bio and the science of degrader antibody conjugates

blonca9
Feb 16, 2024
1 min read

Updated: Feb 23, 2024

Firefly Bio emerged from stealth yesterday with a $94M series A. Co-Founder Carolyn Bertozzi introduces the company and explains the idea behind combining the science of antibody-drug conjugates with protein degraders.

Recent Posts

See All

Checking in with MoonLake's CEO ahead of one of biotech's most closely watched trial readouts of the year - the phase 3 VELA program of sonelokimab in HS (due in Sept)

KalVista's CEO discusses today's FDA approval and commercial launch of Ekterly, the first oral therapy for treating hereditary angioedema (HAE) attacks

AI News: Singapore based Gero, a company focused on small molecules for aging conditions, launched ProtoBind-Diff, a model using amino acid sequences rather than structure models for discovery

Nobel laureate Carolyn Bertozzi on the launch of Firefly Bio and the science of degrader antibody conjugates

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight